Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients

NCT02327689 Phase 4 UNKNOWN

This study evaluates generic emtricitabine(FTC) plus adefovir dipivoxil in Chinese naive HBV related cirrhosis patients. Patients were divided into 2 groups: compensated HBV related cirrhosis patients and decompensated HBV related cirrhosis patients.

Details

Lead sponsor	Asian-Pacific Alliance of Liver Disease, Beijing
Phase	Phase 4
Status	UNKNOWN
Enrolment	400
Start date	2015-01
Completion	2017-07

Conditions

• Hepatitis B, Chronic
• Fibrosis

Interventions

• Emtricitabine plus adefovir dipivoxil

Primary outcomes

• virological response rate — week 96
  HBV DNA \< 500 copies/ml